InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the detailed record of transactions filed by ABERCROMBIE GEORGE B, Directeur. Director active across 1 companies, notably Biocryst Pharmaceuticals INC. Aggregated, 15 filings have been recorded. Total volume traded: €146k. The latest transaction was filed on 7 June 2022 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
012,866 shares0
Common Stock
SEC:0001127602-22-017153:0·
€15,3965,000 shares@ €3.07930.0009% mcap5.0% of flow
Common Stock
SEC:0001127602-22-012272:0·
€14,6825,000 shares@ €2.93640.0009% mcap4.7% of flow
Common Stock
SEC:0001127602-22-005295:0·
€14,5085,000 shares@ €2.90170.0009% mcap10.3% of flow
Common Stock
SEC:0001127602-21-029440·
€14,5085,000 shares@ €2.90170.0009% mcap4.7% of flow
Common Stock
SEC:0001127602-21-029440:0·
€11,1255,000 shares@ €2.2250.0007% mcap7.9% of flow
Common Stock
SEC:0001127602-21-025496·
€11,1255,000 shares@ €2.2250.0007% mcap3.6% of flow
Common Stock
SEC:0001127602-21-025496:0·
€15,90611,000 shares@ €1.4460.0010% mcap11.3% of flow
Common Stock
SEC:0001127602-21-025252·
€15,90611,000 shares@ €1.4460.0010% mcap5.1% of flow
Common Stock
SEC:0001127602-21-025252:0·
€11,1335,000 shares@ €2.22660.0007% mcap7.9% of flow
Common Stock
SEC:0001127602-21-022226·
€11,1335,000 shares@ €2.22660.0007% mcap3.6% of flow
Common Stock
SEC:0001127602-21-022226:0·
€14,3556,667 shares@ €2.15320.0009% mcap10.2% of flow
Common Stock
SEC:0001127602-21-018061·
€14,3556,667 shares@ €2.15320.0009% mcap4.6% of flow
Common Stock
SEC:0001127602-21-018061:0·
€73,2237,000 shares@ €10.46050.0044% mcap52.2% of flow
Common Stock
SEC:0001127602-21-016433·
€73,2237,000 shares@ €10.46050.0044% mcap23.6% of flow
Common Stock
SEC:0001127602-21-016433:0·
15 of 15 declarations
About ABERCROMBIE GEORGE B
George B. Abercrombie is a Director at BIOCRYST PHARMACEUTICALS INC. In this role, he contributes to the governance of the company and the development of strategies aimed at improving performance. His experience in the pharmaceutical sector allows him to provide valuable insights on innovation and research. He is committed to supporting the company's growth initiatives.
